Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the ...

Glenmark Pharmaceuticals launches Tevimbra, a new lung cancer treatment drug, in India. This marks Glenmark's entry into ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

Host Cell Protein ELISA Kits represent essential tools in biopharmaceutical development, providing critical analytical support for the detection and quantification of process-related impurities.

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of daraxonrasib over 15 years. The royalty rate begins at 4.55% on the first $2 ...

Glenmark Pharmaceuticals has launched the lung cancer drug Tevimbra in India after approval by the Central Drugs Standard Control Organisation. Developed by global oncology leader BeiGene, now BeOne ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

Preoperative stereotactic radiation therapy (SRT) could expedite treatment for cancer patients with brain metastases and is as safe as postoperative SRT, according to preliminary findings published in ...

Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO).

Glenmark Pharma launches Tevimbra in India to treat lung and esophageal cancer: Our Bureau, Mumbai Tuesday, June 24, 2025, 14:15 Hrs [IST] Glenmark Pharmaceuticals Ltd, a research ...